Genentech letter warns of stroke risk with ranibizumab

South San Francisco-Genentech Inc. is advising ophthalmologists that it is seeing a slightly higher incidence of stroke among patients using the 0.5-mg dose of its ranibizumab injection (Lucentis) to treat wet age-related macular degeneration (AMD).

Related Videos
Related Content

Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101

March 29th 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

Jumping into gene therapy with collaboration, innovation

March 29th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Unity Biotechnology announces results from Part A of the Phase 2 ENVISION study of UBX1325

March 28th 2023

Ocugen announces FDA approval for enrollment of pediatric patients in ongoing OCU400 Phase 1/2 clinical trial

March 28th 2023

Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101

March 29th 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

Jumping into gene therapy with collaboration, innovation

March 29th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Unity Biotechnology announces results from Part A of the Phase 2 ENVISION study of UBX1325

March 28th 2023

Ocugen announces FDA approval for enrollment of pediatric patients in ongoing OCU400 Phase 1/2 clinical trial

March 28th 2023

Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101

March 29th 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

Jumping into gene therapy with collaboration, innovation

March 29th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Unity Biotechnology announces results from Part A of the Phase 2 ENVISION study of UBX1325

March 28th 2023

Ocugen announces FDA approval for enrollment of pediatric patients in ongoing OCU400 Phase 1/2 clinical trial

March 28th 2023
© 2023 MJH Life Sciences

All rights reserved.